Geron Corp stock (US3741631036): new stock option grants keep hiring momentum in focus
Geron Corp has awarded new stock options to five recent hires under Nasdaq's inducement rules, signaling continued team expansion as the company advances its commercial-stage blood cancer franchise. These grants are designed to attract talent in critical functions without requiring shareholder approval, reflecting a common biotechnology practice to align new employees with long-term value creation. The move underscores Geron's growth following regulatory progress with its lead asset, imetelstat, a telomerase inhibitor for hematologic malignancies.
Five new Geron hires receive options for 333,750 shares
Geron (Nasdaq: GERN) granted stock options for an aggregate 333,750 shares to five new employees on May 15, 2026. These inducement awards, with an exercise price of $1.29 per share, have a ten-year term and a four-year vesting schedule, aligning with Nasdaq Listing Rule 5635(c)(4). The grants are part of Geron's ongoing efforts as a commercial-stage biopharmaceutical company focusing on blood cancer treatments.
GERN Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Geron Corp (GERN), detailing its revenue breakdown, profitability margins, and a comparison with competitors. GERN boasts a high gross margin of 96.74% but shows negative operating and net margins, as well as a negative Return on Equity. The article also benchmarks GERN against industry leaders SEPN and MRVI, highlighting its market capitalization and gross margin performance relative to them.
Deep Track (GERN) reports 31.7M shares, 4.95% ownership (May 2026)
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an amended Schedule 13G/A, disclosing beneficial ownership of 31,720,278 shares of Geron Corp. (GERN) common stock, representing 4.95% of the class. The filing indicates shared voting and dispositive power over these shares, calculated against 640,544,661 outstanding shares as of February 20, 2026. This passive investment report indicates the stake is below 5%, with future disclosures only required for changes in ownership or classification.
RYTELO study: 37.5% of transfusion-dependent went 8 weeks transfusion-free
Geron (Nasdaq: GERN) announced that the first real-world evidence study of its drug RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS) will be presented at EHA 2026. The study, conducted at Moffitt Cancer Center, involved 40 heavily pretreated, transfusion-dependent LR-MDS patients and showed that 37.5% achieved red blood cell transfusion independence for at least eight weeks, with a safety profile consistent with previous data. Geron will also present updated myelofibrosis overall survival data and early-phase acute myeloid leukemia and myelofibrosis combination trial data at EHA 2026 and ASCO 2026.
Is Geron (GERN) One of the Best US Stocks Under $5 to Buy?
Geron Corporation (NASDAQ: GERN) is highlighted as one of the best US stocks under $5, with Wedbush reiterating an Outperform rating and a $5 price target. The company reported strong Q1 2026 net product revenue of $51.8 million from RYTELO, an 8% increase from Q4 2025, and maintains its 2026 revenue guidance between $220 million and $240 million. Geron is also advancing investigator-sponsored trials for RYTELO and strengthening its supply chain.
Geron Corporation (NASDAQ:GERN) Receives Average Recommendation of "Hold" from Analysts
Geron Corporation (NASDAQ:GERN) has received an average "Hold" rating from six analysts, with two recommending "sell," two "hold," and two "buy." The consensus 12-month price target for the stock is $2.50, significantly higher than its current trading price of $1.39. Despite the mixed analyst sentiment, Geron recently surpassed earnings and revenue expectations in its latest quarterly report, driven by progress with its lead drug candidate, imetelstat.
Geron Corporation (NASDAQ:GERN): Is Breakeven Near?
This article analyzes Geron Corporation's financial performance and future profitability outlook, assessing if and when the company might reach breakeven. It will likely delve into recent earnings, expenses, and revenue projections to determine the path to financial sustainability for the pharmaceutical company.
Can Geron’s (GERN) Narrowing Losses Reframe Expectations For Its Blood Cancer Earnings Potential?
Geron Corporation reported improved first-quarter 2026 results with revenue rising to US$51.84 million and net loss narrowing significantly to US$3.64 million due to its commercial ramp. This improvement supports the short-term earnings narrative but the company still faces risks such as single-drug dependence and capital needs for its expanding pipeline. Upcoming investor conferences are expected to provide more details on how these results align with future revenue guidance and diversification plans for its blood cancer programs.
GERN Stock Slips As Traders Weigh Biotech Cash Burn
Geron Corporation (GERN) stock has slipped by 6.96% as traders evaluate its financial profile, characterized by significant cash reserves but ongoing losses typical of a development-stage biotech. The company holds strong liquidity with $312.4M in cash against $73.6M in current liabilities, providing a substantial runway for R&D despite quarterly operating cash outflows of $62.9M. Technical analysis indicates a short-term downtrend with resistance forming, prompting traders to seek quick scalps rather than long-term positions until clearer catalysts or trend changes emerge.
Geron (GERN) Q1 2026 Earnings Call Transcript
Geron (GERN) reported strong Q1 2026 financial results with RYTELO net revenue up 31% year-over-year to $51.8 million, placing the company on track for its $220-$240 million annual guidance. The earnings call highlighted strategic priorities including continued U.S. commercial execution for RYTELO, advancement of European commercial and pricing strategies, and maintaining financial discipline with reduced operating expenses. Management also expects interim analysis results from the IMpactMF trial in relapsed/refractory myelofibrosis in H2 2026, which could further support the disease-modifying potential of imetelstat.
Geron Corp reports results for the quarter ended March 31 - Earnings Summary
Geron Corp has released its earnings summary for the quarter ended March 31. The report, provided by Refinitiv, gives an overview of the company's financial performance. This information is critical for investors and analysts following GERN.
Geron 1Q Loss/Shr 1c >GERN
Geron reported a first-quarter loss per share of 1 cent. The company's stock symbol is GERN.
[10-Q] GERON CORP Quarterly Earnings Report
Geron Corporation has released its quarterly earnings report (Form 10-Q) for the period ended March 31, 2026. The report details the company's financial performance, including a net loss of $3.6 million, an increase in product revenue from RYTELO, and significant research and development expenses. It also discusses ongoing legal proceedings, risk factors related to RYTELO's commercialization, regulatory approvals, intellectual property, and financial stability, emphasizing the company's dependence on RYTELO's success and its need for careful capital management.
Geron: Q1 Earnings Snapshot
Geron Corp. (GERN) reported a first-quarter loss of $3.6 million, or 1 cent per share, which exceeded Wall Street expectations. Analysts surveyed by Zacks Investment Research had predicted a loss of 3 cents per share. The drugmaker also announced revenue of $51.8 million for the period.
Geron Corporation Reports $290.6 Million in Cash Reserves for First Quarter 2026
Geron Corporation announced its financial results for the first quarter of 2026, reporting $290.6 million in cash and marketable securities as of March 31, 2026. The company also detailed research and development expenses of $29.4 million and general and administrative costs of $11.3 million for the quarter. Geron continues to advance its clinical development programs and prepare for potential regulatory submissions.
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
Geron Corporation announced its first-quarter 2026 financial results, reporting RYTELO net product revenue of $51.8 million, an 8% increase from Q4 2025. The company reiterated its full-year 2026 guidance for RYTELO net product revenue ($220M-$240M) and total operating expenses ($230M-$240M) and highlighted progress in commercial strategy and leadership appointments. Geron ended Q1 2026 with $341 million in cash, cash equivalents, restricted cash, and marketable securities, with a net loss of $3.6 million.
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
Geron Corporation announced strong first-quarter 2026 financial results, achieving $51.8 million in RYTELO net product revenue, an 8% increase from the previous quarter. The company reiterated its 2026 revenue guidance of $220 million to $240 million and detailed strategic initiatives including European commercial strategy development, advancement of its Phase 3 IMpactMF trial, and overall financial discipline. Geron also reported a significant decrease in net loss compared to Q1 2025, largely due to increased RYTELO revenue and reduced operating expenses.
Geron: Q1 Earnings Snapshot
Geron Corp. (GERN) reported a first-quarter loss of $3.6 million, or 1 cent per share, which surpassed Wall Street's expectations. Analysts had projected a loss of 3 cents per share. The drugmaker also announced revenues of $51.8 million for the period.
Geron: Q1 Earnings Snapshot
Geron Corp. (GERN) reported a first-quarter loss of $3.6 million, or 1 cent per share, which surpassed Wall Street expectations. Analysts surveyed by Zacks Investment Research had predicted a loss of 3 cents per share. The drugmaker also announced revenues of $51.8 million for the period.
Geron Plans to Present at Upcoming Investor Conferences
Geron Corporation announced that its management team will present at two upcoming investor conferences in May 2026: the Bank of America Securities 2026 Healthcare Conference and the 2026 Stifel Virtual Targeted Oncology Forum. Live and archived audio webcasts of these presentations will be available on the company's website. Geron is a commercial-stage biopharmaceutical company focused on blood cancer treatments, including its approved telomerase inhibitor RYTELO® for myelodysplastic syndromes.
Geron earnings loom: Can RYTELO revenue sustain commercial momentum?
Geron Corporation is set to report its first-quarter earnings, with analysts anticipating a loss of 2 cents per share on $50.1 million in revenue. The focus will be on RYTELO sales to determine if the company can meet its 2026 revenue guidance and demonstrate progress toward profitability amidst scrutiny of operating expenses and pipeline advancements for its blood cancer treatment. Investors will be looking for signs of sustained commercial momentum for RYTELO and disciplined cost management.
Geron Plans to Present at Upcoming Investor Conferences
Geron Corporation announced that its management team is scheduled to present at two upcoming investor conferences: the Bank of America Securities 2026 Healthcare Conference and the 2026 Stifel Virtual Targeted Oncology Forum. The company, a commercial-stage biopharmaceutical firm, aims to highlight its efforts in changing the course of blood cancer, including its approved telomerase inhibitor RYTELO® (imetelstat). Webcasts of these presentations will be available on Geron's website.
Geron (GERN) to Release Earnings on Wednesday
Geron (GERN) is scheduled to release its Q1 2026 earnings before market open on Wednesday, May 6th. Analysts anticipate an EPS of ($0.03) and revenue around $50.1 million. The biopharmaceutical company previously missed Q4 estimates, reporting an EPS of ($0.05) against an expected ($0.03), and currently holds a consensus "Hold" rating with an average price target of $2.17.
Geron Corporation (GERN) Appoints Timothy Williams as EVP, Chief Legal Officer
Geron Corporation (GERN) announced the appointment of Timothy Williams as Executive Vice President, Chief Legal Officer, and Corporate Secretary. Williams, formerly General Counsel at Vanda Pharmaceuticals, brings extensive legal experience from various biopharma and legal roles. This strategic addition aims to bolster Geron's leadership as it commercializes its treatment for lower-risk myelodysplastic syndromes and pursues long-term growth objectives.
Geron Corporation (GERN) Appoints Timothy Williams as EVP, Chief Legal Officer
Geron Corporation (NASDAQ: GERN) has appointed Timothy Williams as Executive Vice President, Chief Legal Officer, and Corporate Secretary. Williams, formerly of Vanda Pharmaceuticals, brings extensive experience to Geron as it advances its commercial strategy for treating myelodysplastic syndromes and aims to strengthen its leadership in sustainable hematology. His appointment is expected to provide invaluable strategic counsel and support the company's long-term growth objectives.
Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026
Geron Corporation announced it will release its first quarter 2026 financial results and business highlights on Wednesday, May 6, 2026, before market open. The biopharmaceutical company, focused on blood cancer treatments, will also host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results.
Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026
Geron Corporation announced it will release its first quarter 2026 financial results and business highlights on Wednesday, May 6, 2026. The company will also host a conference call and webcast at 8:00 a.m. Eastern Time. Geron is a commercial-stage biopharmaceutical company focused on blood cancer, with an approved telomerase inhibitor, RYTELO (imetelstat).
Geron sets May 6 financial update with webcast before market open
Geron Corporation (NASDAQ: GERN) announced it will release its first quarter 2026 financial results and business highlights on May 6, 2026, before market open. The company will also host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results. Historically, similar announcements have led to mild market reactions.
Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026
Geron Corporation announced it will release its first quarter 2026 financial results and business highlights on Wednesday, May 6, 2026, before the market opens. The company will also host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results. Geron, a commercial-stage biopharmaceutical company focusing on blood cancer, has its telomerase inhibitor RYTELO® approved in the U.S. and EU.
Nine new Geron hires receive options at $1.68 a share
Geron Corporation announced the grant of 855,000 inducement stock options to nine newly hired employees, effective April 17, 2026. The options have an exercise price of $1.68 per share, a 10-year term, and vest over four years. This move aligns with Geron's ongoing strategy of team expansion and corporate build-out, following similar grants and governance updates.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced it granted stock options to nine new employees as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These options cover 855,000 shares at an exercise price of $1.68 per share, vesting over four years. Geron is a commercial-stage biopharmaceutical company focused on blood cancer, with its telomerase inhibitor RYTELO® approved for certain myelodysplastic syndromes.
Geron (NASDAQ:GERN) Stock Price Down 5.1% - Here's What Happened
Geron's stock (NASDAQ:GERN) saw a 5.1% decline on Monday, trading at $1.595, with significantly reduced volume. This drop follows the company missing quarterly earnings and revenue expectations. Analysts currently have a "Hold" consensus rating for Geron, with an average price target of $2.17.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced the grant of stock options to nine new employees as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These options, totaling 855,000 shares of common stock, have an exercise price of $1.68 per share and a ten-year term, vesting over four years. Geron is a commercial-stage biopharmaceutical company focused on blood cancer, with its telomerase inhibitor RYTELO® approved for certain myelodysplastic syndromes.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced that it granted stock options to nine newly hired employees, totaling 855,000 shares of common stock, as an inducement for their employment. The options have an exercise price of $1.68 per share and vest over four years. This action was taken in accordance with Nasdaq Listing Rule 5635(c)(4).
Geron Corporation (NASDAQ:GERN) Short Interest Up 21.3% in March
Short interest in Geron Corporation (NASDAQ:GERN) surged by 21.3% in March, reaching 76.67 million shares, which represents about 12.9% of the float. This increase indicates a growing bearish sentiment, despite high institutional ownership and analyst ratings that are mostly "Hold" with a consensus target price of $2.17. The biopharmaceutical company recently missed its quarterly earnings estimates and has a market capitalization of $1.08 billion.
Geron taps former Vanda counsel Timothy Williams for top legal post
Geron (Nasdaq: GERN) announced the appointment of Timothy Williams as Executive Vice President, Chief Legal Officer, and Corporate Secretary. Williams, formerly with Vanda Pharmaceuticals, brings extensive biopharmaceutical legal experience in M&A, corporate governance, securities, and compliance. This strategic hire is expected to strengthen Geron's leadership team as it advances its strategy in hematology, particularly following the successful commercialization of RYTELO®.
New Geron legal chief gets option to buy 2.5M shares at $1.73
Geron Corporation announced it granted Timothy Williams, its new Executive Vice President, Chief Legal Officer, and Corporate Secretary, a stock option to purchase 2,500,000 shares. The option was granted on April 13, 2026, with an exercise price of $1.73 per share, matching the closing price on the grant date. This inducement award vests over four years and was approved under Nasdaq Listing Rule 5635(c)(4).
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation granted a stock option to purchase 2,500,000 shares of its common stock to Timothy Williams, the new Executive Vice President, Chief Legal Officer, and Corporate Secretary. This equity award, granted on April 13, 2026, serves as an inducement for his employment. The option has an exercise price of $1.73 per share, a ten-year term, and vests over four years, subject to continued service.
Geron Adds Chief Legal Officer As Equity Ties To Execution Risk
Geron has appointed Timothy Williams as Executive Vice President, Chief Legal Officer, and Corporate Secretary, with an equity award as an inducement. This hire adds crucial legal and compliance experience for a commercial-stage biopharmaceutical company like Geron. The stock options tie Williams' compensation to the company's long-term performance, aligning his incentives with shareholder outcomes as Geron expands its commercial activities.
Geron (GERN) grants 2.5M stock options to chief legal officer
Geron Corp. (GERN) has granted 2.5 million stock options to its EVP and Chief Legal Officer, Timothy Williams, with an exercise price of $1.73 per share and an expiration date of April 12, 2036. The options will begin vesting on October 13, 2026, with the remaining shares vesting in equal installments over the subsequent 42 months, contingent on his continued employment. This award is compensation-related and not an open-market transaction.
Geron (GERN) EVP and Chief Legal Officer files initial Form 3 insider report
Geron's EVP and Chief Legal Officer, Timothy Williams, has filed an initial Form 3 insider report, establishing his reporting person status with the SEC. This filing indicates no current beneficial ownership or transactions, serving purely as a baseline regulatory disclosure. The report confirms his role and signifies his obligation to report future changes in his ownership of company securities.
Geron Corp stock (US3741631036): Is imetelstat approval the real test for biotech upside?
Geron Corp's lead drug, imetelstat, targets an unmet need in blood cancers, particularly myelodysplastic syndromes (MDS), and its potential approval could be a significant upside catalyst for the biotech company. The company has dedicated years to developing this telomerase inhibitor, which is now in pivotal trial stages and has positive Phase 3 data for MDS patients. If approved, imetelstat could address a multi-billion dollar market, with potential for label expansion into other hematologic malignancies.
Geron Corp stock (US3741631036): Is imetelstat approval the real test for biotech upside?
Geron Corp's lead drug, imetelstat, a telomerase inhibitor, is positioned to address an unmet need in blood cancers like myelodysplastic syndromes (MDS). Its potential FDA approval could significantly impact the biotech's valuation and the broader market for novel cancer treatments, especially for U.S. investors. The company's focused strategy on imetelstat, bolstered by positive Phase 3 data and analyst support, makes it a high-upside, high-risk play in the biopharmaceutical sector.
Geron Grants Legal Chief 2.5M-Share Option
Geron Corporation, a biopharmaceutical company, has awarded its new Executive Vice President, Chief Legal Officer and Corporate Secretary, Timothy Williams, an equity grant of 2.5 million stock options. This inducement grant, a common practice in the biotech industry, aims to attract and retain top talent like Williams, who will be crucial in the company's efforts to expand the commercial and regulatory reach of its telomerase inhibitor drug RYTELO. The stock option has a ten-year term, an exercise price of $1.73 per share, and vests over four years, with an initial 12.5% vesting after six months.
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Geron Corporation announced an inducement grant in accordance with Nasdaq Listing Rule 5635(C)(4). The brief report, attributed to Refinitiv, indicated that this news is subject to copyright by Thomson Reuters.
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced an inducement grant of a stock option to purchase 2,500,000 shares of its common stock to Timothy Williams, the new Executive Vice President, Chief Legal Officer and Corporate Secretary. This equity award is material to his acceptance of employment with the company. The grant was reported under Nasdaq Listing Rule 5635(c)(4).
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced an inducement grant of a stock option to purchase 2,500,000 shares of its common stock to Timothy Williams, the new Executive Vice President, Chief Legal Officer, and Corporate Secretary. This grant, made on April 13, 2026, has an exercise price of $1.73 per share and vests over four years, in accordance with Nasdaq Listing Rule 5635(c)(4). Geron is a commercial-stage biopharmaceutical company focused on blood cancer treatments.
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation granted an inducement equity award to Timothy Williams, the new Executive Vice President, Chief Legal Officer, and Corporate Secretary. The stock option is for 2,500,000 shares of common stock with an exercise price of $1.73 per share, vesting over four years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and is part of Geron's 2018 Inducement Award Plan.
Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary
Geron Corporation, a biopharmaceutical company focused on blood cancer, has announced the appointment of Timothy Williams as Executive Vice President, Chief Legal Officer, and Corporate Secretary. Williams brings extensive experience from previous roles at Vanda Pharmaceuticals and AgNovos Bioscience, and his expertise is expected to support Geron's commercial strategy and goal of becoming a leading hematology company. The company highlighted his strategic counsel as invaluable for advancing their objectives.
